UBS backs Medartis on strong U.S. Keri TOUCH rollout, margin upside

UBS upgraded Medartis Holding (MEDA) to “buy” from “neutral,” lifting its 12-month target to CHF97 from CHF87 on faster U.S. adoption of its Keri TOUCH thumb prosthesis. UBS expects U.S. penetration to rise to ~10% by 2030 (implying ~CHF76M TOUCH sales), with 2026 organic revenue growth of 18.0% to CHF332M (slightly ahead of consensus CHF330M) and a 19.1% core EBITDA margin vs consensus ~19% (consensus core EBITDA ~CHF59M). The bank raised 2026-2028 EPS estimates by an average 7% and argues the ~17.7x 2026 EV/EBITDA multiple is justified by a ~20% core EBITDA CAGR vs ~12% for peers.

Analysis

The market is likely underappreciating how much of the upside here comes from mix, not just volume. If the U.S. launch keeps converting trained surgeons into repeat users, this becomes a leverage story: each incremental case should carry better economics than the base business, so the valuation gap to broader ortho names can persist even if headline growth moderates. The second-order implication is that the real competitive threat is not the large diversified medtechs but smaller upper-extremity specialists and distributor-heavy channels that lose share whenever a proprietary workflow becomes embedded.

Near term, this is a sentiment-driven rerating setup into the Aug. 18 print; the stock can work for days to weeks if management confirms the adoption slope and gives any hint of forward order visibility. The risk is that early surgeon training converts into trials, not durable cadence, which is common in procedure-based launches. If case volumes or gross margin progression disappoint, the premium multiple can compress quickly toward peer territory because the current valuation already capitalizes a successful rollout.

The contrarian view is that consensus may be extrapolating a straight-line penetration curve in a market that usually ramps in steps, with reimbursement friction, inventory placement, and surgeon loyalty creating lumpy adoption. The thesis weakens materially if H1 shows slower-than-expected repeat procedures, higher launch spend, or no evidence that U.S. contribution margin is inflecting. In that scenario, the right response is not to buy the dip mechanically; it is to wait for evidence that the installed base is becoming sticky before paying for the growth premium.

Key Decisions for Investors

• Initiate a small tactical long in MDRSF on pullbacks ahead of Aug. 18, but only if liquidity allows patient limit orders; treat it as a 1-3 month catalyst trade rather than a core hold.
• Pair trade: long MDRSF / short SMNEY over 3-6 months to isolate upper-extremity U.S. adoption alpha versus broader orthopaedic exposure; thesis breaks if MDRSF fails to show repeat-case conversion.
• Set an alert for the Aug. 18 H1 release: if U.S. case cadence annualizes below the implied launch trajectory or SG&A rises faster than revenue, expect multiple compression toward 13-15x EV/EBITDA.
• If you need lower-risk exposure, wait for confirmation and buy the name only after the print confirms margin expansion; the valuation can still work, but the entry point improves materially if the first-half update is merely adequate rather than exceptional.